Independent. Inquisitive. Virginia.
THE VIRGINIA EDITION
The VirginianYour state. In your inbox.Explore the briefings →
Explore Virginia +

Business & Innovation · news

Microscope and empty culture dish on a laboratory bench
Microscope and empty culture dish on a laboratory bench — editorial illustration

Virginia Tech’s $3.82 million cell-therapy project moves the laboratory toward the patient

A five-year NIH award supports an experimental patch, with initial safety and effectiveness testing planned in mice.

By The Virginian News · Published November 9, 2026

A Virginia Tech researcher has secured a $3.82 million NIH Director’s New Innovator Award to test whether a small patch could perform work now done in specialized cell-therapy laboratories. The five-year project is an early research effort, not an available treatment.

Wujin Sun, an assistant professor of biological systems engineering, is developing a “transdermal bioreactor.” The proposed device would draw a patient’s cells into a soft material beneath the skin, deliver instructions that change their function, and release them back into the body.

The first targets are melanoma and chronic wounds associated with diabetes. Virginia Tech says the team will use mice to investigate safety and effectiveness. Those experiments are a necessary distinction from evidence of benefit in people.

The project addresses the manufacturing burden behind advanced cell therapies: preparing customized cells can require costly facilities and substantial time. Moving some of that work to a patch could change how treatments are produced, if the approach proves successful. Sun was among 42 researchers selected for the 2026 award, part of NIH’s high-risk, high-reward research program.

Virginia Tech

Related coverage